Indianapolis, IN, United States of America

Jolie Anne Bastian

This inventor holds 32 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Cancer Therapeutics. Top assignee: Eli Lilly and Company. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jolie Anne Bastian. Retrieved from https://idiyas.com/inventor/jolie-anne-bastian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 32 (Patent Applications = 2)

% Patents Active = 65.6

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 92(Granted Patents)

Location History:

Beech Grove, IN (US) (2000 - 2007)
Indianapolis, IN (US) (2010 - 2024)

Company Filing History:

32 out of 4,517

Eli Lilly and Company

patents

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

KRas Inhibitors

Selective Estrogen Receptor Degraders

JAK Inhibitors

Antithrombotic Agents

Tetrasubstituted Pyridazines

Glycine Derivatives

Oxindole Agonists

Phthalazine Compounds

Hedgehog Pathway Antagonists

Tricyclics

Diamines

Factor Xa Inhibitors

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723053 - KRas inhibitors (2026-09-01),

2. 12351591 - KRas inhibitors (2025-07-08),

3. 11993608 - Selective estrogen receptor degraders (2024-05-28),

4. 11634426 - Selective estrogen receptor degraders (2023-04-25),

5. 11117902 - Selective estrogen receptor degraders (2021-09-14),

6. 10759786 - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer (2020-09-01),

7. 10654866 - Selective estrogen receptor degraders (2020-05-19),

8. 10344018 - Pyrazolylaminobenzimidazole derivatives as JAK inhibitors (2019-07-09),

9. 10323019 - Pyrazolylaminobenzimidazole derivatives as JAK inhibitors (2019-06-18),

10. 9872853 - 2,3-dihydro-1H-indole compounds (2018-01-23),

11. 8507490 - Tetrasubstituted pyridazine hedgehog pathway antagonists (2013-08-13),

12. 8445493 - Tetrasubstituted pyridazines hedgehog pathway antagonists (2013-05-21),

13. 8404687 - Disubstituted phthalazine hedgehog pathway antagonists (2013-03-26),

14. 7652015 - Kinase inhibitors (2010-01-26),

15. 7297706 - Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders (2007-11-20),

Title: Innovations and Contributions of Jolie Anne Bastian

Introduction

Jolie Anne Bastian is a prolific inventor based in Indianapolis, IN, recognized for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of 30 patents, Bastian has made a notable impact on the development of selective estrogen receptor degraders.

Latest Patents

Among her latest patents, Jolie Anne Bastian has developed novel selective estrogen receptor degraders (SERDs). These innovative compounds are characterized by the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In these formulations, either R or R' is independently selected from Cl, F, —CF, or —CH, while the other is hydrogen. The methods for their use are also meticulously detailed, showcasing Bastian's expertise in pharmaceutical innovations.

Career Highlights

Bastian’s career is marked by her role at Eli Lilly and Company, where she actively contributes to cutting-edge research and development. Her work focuses on creating therapeutic solutions that address various health challenges, particularly in hormone-related conditions.

Collaborations

Throughout her career, Jolie Anne Bastian has collaborated with notable colleagues, including Daniel Jon Sall and Theo Schotten. These partnerships reflect a commitment to advancing scientific knowledge and producing innovative solutions within the pharmaceutical landscape.

Conclusion

Jolie Anne Bastian's work exemplifies the spirit of innovation in the pharmaceutical industry. With her extensive patent portfolio and collaborative approach, she continues to drive advancements that contribute to improved healthcare solutions.

Profile summary based on public USPTO records.